Trial Profile
A single dose ascending and repeated dose, randomised, double-blind, placebo-controlled study to assess the safety, pharmacokinetics and pharmacodynamics of CSL324 in healthy, adult male and female subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Anumigilimab (Primary) ; Cantharidin; Filgrastim
- Indications Immunological disorders; Inflammation; Rheumatic disorders
- Focus Adverse reactions; First in man
- Sponsors CSL
- 24 Jan 2023 Results published in the British Journal of Dermatology
- 29 Nov 2018 Status changed from active, no longer recruiting to completed.
- 11 Oct 2017 Status changed from recruiting to active, no longer recruiting.